Impact Factor 2019: 1.940 (@Clarivate Analytics)
5-Year Impact Factor: 1.955 (@Clarivate Analytics)
  • Users Online: 2277
  • Print this page
  • Email this page

 
Table of Contents
GUIDELINES
Year : 2020  |  Volume : 13  |  Issue : 4  |  Page : 152-161

Expert consensus guidelines on clinical use of Xiyanping injection for acute infectious diseases


1 Emergency Branch of China Association of Chinese Medicine
2 Chinese College of Emergency Physicians of Chinese Medical Doctor Association
3 Emergency Branch of World Federation Chinese Medicine Societies
4 Emergency Branch of China Association of Promoting Traditional Medicine
5 Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University
6 Research Unit of Island Emergency Medicine, Chinese Academy of Medical Sciences, Hainan Medical University
7 Key Laboratory of Traditional Chinese Medicine for Prevention and Control of Infectious Diseases, Guangdong Province Traditional Chinese Medical Hospital

Date of Submission05-Feb-2020
Date of Decision19-Feb-2020
Date of Acceptance27-Feb-2020
Date of Web Publication25-Mar-2020

Correspondence Address:
Banghan Ding
Guangdong Provincial Traditional Chinese Medical Hospital, Guangzhou 510120, China

Bangjiang Fang
Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Chuanzhu Lv
Hainan Medical University, Haikou 570102, China

Jun Li
Guangdong Provincial Traditional Chinese Medical Hospital, Guangzhou 510120, China

Qingquan Liu
Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China

Xiaodong Zhao
Fourth Medical Center of PLA General Hospital, Beijing 100010, China

Xuezhong Yu
Peking Union Medical College Hospital, Beijing 100730, China

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.280222

Get Permissions

  Abstract 


Xiyanping injection, a traditional Chinese medicine injection made of andrographolide sulfonate, consisting of well-defined ingredients with antiviral, antibacterial, anti-inflammatory and antipyretic efficacy, has been widely used for treating infectious diseases of respiratory and digestive systems. However, its wide applications may easily lead to unreasonable clinical medication. In order to guide the precise clinical application and rational use of Xiyanping injection, experts in related fields conducted systematically literature review, evaluated and deliberated the application of Xiyanping injection in treating acute infectious diseases using evidence-based medicine method, and jointly drafted the consensus to summarize types of acute infectious diseases in children and adults that can be treated with Xiyanping injection, and recommend the intervention time, usage and dosage, course of treatment and combined medication of the injection. Besides, the consensus elucidates the safety, precautions and contraindications of the injection, so as to provide guidance for clinical use.

Keywords: Xiyanping injection; Expert consensus; Acute infectious diseases; Evidence-based medicine


How to cite this article:
Ding B, Fang B, Li J, Liu Q, Lv C, Yu X, Zhao X. Expert consensus guidelines on clinical use of Xiyanping injection for acute infectious diseases. Asian Pac J Trop Med 2020;13:152-61

How to cite this URL:
Ding B, Fang B, Li J, Liu Q, Lv C, Yu X, Zhao X. Expert consensus guidelines on clinical use of Xiyanping injection for acute infectious diseases. Asian Pac J Trop Med [serial online] 2020 [cited 2020 Sep 30];13:152-61. Available from: http://www.apjtm.org/text.asp?2020/13/4/152/280222




  1. Introduction Top


Xiyanping injection is a traditional Chinese medicine injection made of andrographolide sulfonate, consisting of well-defined ingredients with the antiviral, antibacterial, anti-inflammatory and antipyretic efficacy. For over 40 years since Xiyanping injection was sold on the market, the injection has been widely used in the treatment of infectious diseases of respiratory and digestive systems. Research on Xiyanping injection has been rewarded and funded by the “Twelfth Five-Year” state project for essential drug research and development, the project for applying advances of high and new technologies in production of National Development and Reform Commission, national major infectious disease prevention and control project, and other scientific research projects successively. The injection was listed as a category B drug in the National drug catalog for basic medical insurance, work-related injury insurance, and maternity insurance. In several guidelines or expert consensuses, Xiyanping injection has been listed as a standard drug and because of its good clinical efficacy and pharmaco-economics benefit[1],[2],[3],[4],[5],[6],[7],[8],[9],[10],[11],[12],[13],[14], it is recommended by National Health Commission,

National Administration of Traditional Chinese Medicine and different professional institutes for the treatment of more than 10 diseases, including influenza, pneumonia, acute fever and hand-foot- and-mouth disease.

Chinese patent medicines like Xiyanping injection are widely used for clinical treatment of acute infectious diseases. In the treatment of acute infectious diseases of respiratory system and digestive system, clinical or laboratory indications are necessary criteria for the use of antibacterial drugs for bacterial infection, so the choice of antiviral drugs for viral infections is very limited, leaving alone the delayed diagnosis since the viral or bacterial pathogens tests are time-consuming. Therefore, as a drug with antiviral, antibacterial, anti-inflammatory and antipyretic effects, Xiyanping injection can be used complementarily with other drugs or used as the first choice drug. On the other hand, irrational use of the injection is a problem[15],[16],[17],[18],[19].

More than 2 300 academic papers studying on the basis and clinical research of Xiyanping injection have been published in recent years (including 359 published in core journals). If these paper findings can be transferred into evidence for clinical use based on evidence- based medicine method, it will provide guidance for recommending indications and principles of using Xiyanping injection, its usage and dosage, as well as combined use of the injection.

Experts from College of Emergency of China Association of Chinese Medicine, Chinese College of Emergency Physicians of Chinese Medical Doctor Association, College of Emergency of World Federation Chinese Medicine Societies, College of Emergency of China Association of Promoting Traditional Medicine, and other associations have made systematically literature review, evaluated and discussed the application of Xiyanping injection for treating acute infectious diseases by evidence-based medicine method, and jointly drafted and formulated the expert consensus on clinical use of Xiyanping injection for treating acute infectious diseases (hereinafter referred to as “consensus”) for the reference of physicians and pharmacists in Emergency Department, Respiratory Department Digestive Department, TCM Internal Medicine Department and Pediatrics Department.

The consensus is formulated mainly based on evidence-based medicine research methods, through a systematical literature review and analysis of published papers on the Xiyanping injection which focused on summarizing experiences of clinical experts Data were mainly retrived from: (1) Papers on Xiyanping injection indexed in Web of Science and PubMed from the earliest collection date till June 2019; (2) papers on Xiyanping injection included in Wanfang and CNKI databases from the earliest collection date utill June 2019; (3) personal experience and opinions of experts.

The criteria for evaluating quality of the evidence based on the GRADE system were summarized in [Table 1].
Table 1: Quality of evidence based on GRADE system.

Click here to view



  2. Basic Information of Xiyanping Injection Top


2.1. Active ingredients

The main components of Xiyanping injection is andrographolide sulfonate. Andrographolide, the effective component of the Andrographis paniculata leaves which is insoluble in water, is made into water solution without the help of excipients through the unique sulfonation process (China excellent patent award, patent No.: ZL01131382.X). Xiyanping injection is capable of improving the efficacy of andrographolide while reducing its adverse effects. The pH of Xiyanping injection is 4.5-6.5, and every 1 mL of Xiyanping injection contains at least 0.50 mg andrographolide sulfonate, which is sodium17-hydro-9-dehydroandrographapholide-19-sulfate (C20H29O5•SO3Na).

2.2. Pharmacokinetics

Studies on the pharmacokinetics and tissue distribution of active ingredients intravenously injected into the rat tail showed that the distribution of Xiyanping injection in the rat plasma accorded with two-compartment model features. The active ingredients spread rapidly in the plasma and tissues, and are mainly distributed in kidneys, intestinal tracts, liver, lungs, heart, etc., and the drug concentration in the kidney is the highest at the 5th minutes after administration[20],[21].

2.3. Pharmacological effects

2.3.1. Antiviral

Xiyanping injection can inhibit influenza A/B virus, parainfluenza virus, respiratory syncytial virus, adenovirus, rhinovirus and Coxsackie virus, showing a dose-effect relationship[22],[23]. Xiyanping injection prevents infection of influenza virus by inhibiting the absorption function of hemagglutinin, and reduces virus proliferation by regulating the cellular immune pathways AKT and NF-kB. It controls the release of progeny virus by inhibiting the expression of Bax protein in the cells infected by adenovirus. The active component XYP-1 blocks the adsorption and proliferation of CVB3 virus, and the active component XYP-2 inhibits the proliferation of CVB-3 virus and directly kills it. Xiyanping injection can also protect a variety of tissues from injury caused by EV71 virus infection through inhibiting ERK and JNK phosphorylation, decreasing the expression of NF-kB pathway inflammatory factors, and improving the activity of T cells to enhance the immunologic function of the body[24],[25],[26],[27],[28].

2.3.2. Antibacterial and anti-Mycoplasma pneumoniae

Xiyanping injection shows depressant effects on Gram-positive bacteria such as enterpathogenic Escherichia coli, Bacillus typhia, Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, Hemolytic streptococcus, and proteus and dysentery bacillus[29],[30],[31]. Combining with cefoxitin, Xiyanping injection has synergistic antibacterial effects and can damage the biofilm of methicillin-resistant Staphylococcus aureus[32].

The minimal inhibitory concentration of Xiyanping injection against Mycoplasma pneumonia can reach 0.52-1.05 μg/mL. When the injection is used together with erythromycin, the minimal inhibitory concentration decreased to 1/8-1/2 of dosage versus erythromycin used alone[33].

2.3.3. Anti-inflammatory and antipyretic

Xiyanping injection prevents the over activation of inflammatory cells, promotes the balance between inflammatory factors and anti- inflammatory media, significantly diminishes the inflammatory lesions, and protects the organs through the following mechanisms: inhibiting intracellular MAPK (p38) and STAT3 pathways, nuclear NF-kB (p65) pathway and the release of several inflammatory factors, and inducing mitochondrial autophagy to impede the synthesis of NLRP3 inflammasome. It exerts the antipyretic effects by decreasing the activation of endogenous pyrogenic cells, lessening the release amount of endogenous pyrogenic IL-1 and TNF-α, and reducing the production of centric fever positive regulatory medium PGE2 and 5-HT[34],[35],[36],[37],[38],[39].

2.4. Cognition of traditional Chinese medicine

Xiyanping injection is extracted from Andrographis paniculata, a traditional Chinese medicine with bitter taste, and it is cold-natured and non-toxic, and its effective components are distributed in heart, lung, large intestine and bladder channels, as recorded in the ancient books and pharmacopoeia. It is also stated in books that Andrographis paniculata can clear away heat and detoxify, cool blood and reduce swelling. It is also capable of treating fever and colds, sore throat, sore tongue, cough, diarrhea, dysentery, hot leaching, swollen sore, snake bites, etc.


  3. Suggestions on Clinical Application of Xiyanping Injection in Treating Acute Infectious Diseases Top


3.1. Acute upper respiratory infection

Acute upper respiratory infection is a group of diseases including common cold, acute viral pharyngitis, herpangina and bacterial pharyngotonsillitis.

A meta-analysis of 15 randomized controlled trials (RCTs) included 2 457 children suggested that compared with ribavirin, Xiyanping injection showed higher total effective rate in the treatment of children with acute upper respiratory infection, and symptoms of coughing and pharyngeal congestion vanished in a shorter time[40].

A meta-analysis of Xiyanping injection combined with ribavirin in the treatment of herpangina enrolled 2 796 children in 23 RCTs. The results suggested that the combined use of Xiyanping injection and ribavirin was significantly superior to the use of ribavirin alone or Xiyanping injection alone from aspects of total effective rate, and the recovery of normal body temperature as well as herpes, length of time to restore normal body temperature, length of time for herpes to disappear[41].

A study of 27 RCTs enrolled 3 485 children with acute tonsillitis suggested that compared with using other antibiotics (penicillin/ clindamycin/azithromycin/non penicillin β-lactam antibiotics) alone, the combined use of Xiyanping injection and antibiotics could improve the total clinical effective rate, length of time to restore normal body temperature, length of time for the disappearance of fever, sore throat, purulent secretion and tonsil enlargement, as well as length of hospital stay. This may be related to the effectiveness of Xiyanping injection in inhibiting the expression of inflammatory factors IL-6, IL-8 and TNF-α. In addition, three clinical studies on adult patients with acute tonsillitis showed that compared with using antibiotics alone, the combined use of Xiyanping injection and antibiotics could improve the total effective rate, and the recovery of normal body temperatures, as well as sore throat[42],[43],[44].

Recommendation: For adults and children with acute upper respiratory infection accompanied by fever (body temperature ≥38 °C) or sore throat or severe coughing, Xiyanping injection can be used to improve clinical symptoms according to individual conditions (Level A).

3.2. Influenza

To evaluated the efficacy of Xiyanping injection combined with oseltamivir, a study of 5 RCTs included 316 cases with influenza showed that[45] compared with using oseltamivir alone, the combination of Xiyanping injection and oseltamivir showed higher total effective rate, shorter time to restore normal body temperatures, shorter hospital stay, and a lower incidence of adverse reactions. The results of another study included 9 RCTs which enrolled 997 patients with influenza showed that[46] Xiyanping injection showed shorter antipyretic time than using antiviral Western medicine (ribavirin/ oseltamivir) alone, but the difference in the total effective rate and adverse reactions between the two groups was not statistically significant.

Recommendation: Identified patients with influenza are recommended to receive the combined use of Xiyanping injection and antiviral Western medicines like oseltamivir in order to shorten the fever time (Level A). In the case that oseltamivir and other antiviral Western medicines cannot be used, Xiyanping injection is recommended as alternative drug to reduce length of fever time (Level B).

3.3. Acute tracheo-bronchitis

Most acute tracheo-bronchitis is caused by respiratory virus infection, such as rhinovirus, coronavirus, influenza virus and respiratory syncytial virus. Only less than 10% cases are caused by bacteria, among which the most common pathogens are Bordetella pertussis, Mycoplasma pneumoniae and Chlamydia pneumoniae[47],[48],[49]. Therefore, supportive treatment, not empirical antibiotic treatment, is recommended for acute tracheo-bronchitis[51],[52]. The results of related studies suggested that the combination of Xiyanping injection and conventional supportive treatment could improve the total effective rate, relieve coughing, shorten the fever time, and accelerate the disappearance of lung and asthma symptoms[53].

Recommendation: For patients with acute tracheo-bronchitis, Xiyanping injection is recommended to be used as early as possible in order to relieve symptoms, shorten the fever time and accelerate the disappearance of lung symptoms (Level A).

3.4. Community acquired pneumonia (CAP)

3.4.1. Bacterial pneumonia

A study of 31 RCTs included 2 881 children with Mycoplasma pneumonia showed that compared with using azithromycin alone, the combined use of Xiyanping injection and azithromycin showed better effects in total effective rate, faster recovery from fever, coughing, lung rales, chest film, and shorter hospital stay, etc..[54] Another study of 18 RCTs showed the combined use of Xiyanping injection and antibiotics in the treatment of 1 924 adult patients with community-acquired pneumonia could improve the clinical treatment efficiency of CAP in adults, relieve coughing, and shorten the time of fever and hospitalization[55]. Additionally, a study including 18 RCTs showed that the combined use of Xiyanping injection and azithromycin in the treatment of 538 elderly patients with community acquired pneumonia could increase the total effective rate, shorten the fever time, relieve coughing, increase the bacterial clearance rate, and shorten the course of disease[56].

Recommendation: For adults and children with CAP caused by bacterial infection or Mycoplasma pneumoniae infection, Xiyanping injection and appropriate antibiotics are recommended to be used as soon as possible at the time choosing antibiotics reasonably, which can help regulate airway inflammation, improve clinical symptoms, and shorten fever time and the disease course (Level A).

3.4.2. Viral pneumonia

Viral pneumonia, commonly seen in children, is the inflammation of lung parenchyma caused by respiratory virus infection. A study of 10 RCTs enrolled 861 children with viral pneumonia showed that compared with ribavirin, Xiyanping injection could shorten the fever time, and accelerate the disappearance of asthma symptoms and lung rales[57]. Another study of 20 RCTs included 2 126 children with viral pneumonia showed that compared with ribavirin or other Chinese patent medicines, Xiyanping injection has more advantages in terms of antipyretic time, disappearance of cough, asthma, lung rales the hospitalization time, etc.

A study of 5 RCTs enrolled 461 adults with viral pneumonia, 3 RCTs evaluated the clinical recovery rate indices, which indicated that Xiyanping injection could improve the recovery rate compared with ribavirin; 2 RCTs evaluated the time of fever, cough and lung rales to disappear, which indicated that Xiyanping injection could shorten the time for cough and lung rales when compared with ribavirin, but the difference in fever time between the two groups was not statistically significant[58].

Recommendation: For adults or children in the early or middle stage of viral pneumonia, Xiyanping injection is recommended to regulate the inflammation reaction, promote the inflammatory absorption in lungs, shorten the hospital stay, prevent disease progressing and decrease the complication rate (Level A).

3.5. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

Most acute exacerbation of chronic obstructive pulmonary disease (COPD) is caused by respiratory infection, and their treatment often includes antibacterial drugs. The results of a study included 1 500 patients in 19 RCTs showed that compared with conventional symptomatic treatment plus antibiotic treatment, conventional symptomatic treatment plus antibiotic plus Xiyanping injection could improve the total effective rate, reduce the leukocyte count and amount of C-reactive protein, shorten the time of cough, expectoration, dyspnea and other symptoms, improve the status of partial pressure of oxygen and carbon dioxide, and the percentage of FEVl in predict value (%)[59],[60].

Global Initiative for Chronic Obstructive Lung Disease (GOLD) report points out explicitly that virus is the main trigger of AECOPD[61]. AECOPD accompanied by virus infection may lead to more obvious airway inflammation and systemic inflammation[62]. The early application of Xiyanping injection which has a wide range of the antipyretic, antiviral and anti-inflammatory efficacy in the treatment of AECOPD may help to balance between pro- inflammatory and anti-inflammatory factors, and reduce the airway inflammation and systemic inflammation[63].

Recommendation: For patients with early to moderate AECOPD, at the time of initial targeted antimicrobial treatment, the combination of Xiyanping injection can reduce airway inflammation, improve clinical symptoms, such as cough, expectoration and antipyretic, and shorten the disease course and hospital stay length (Level C).

3.6. Hand-foot-and-mouth Disease (HFMD)

A study of 10 RCTs showed that the addition of Xiyanping injection on the basis of conventional treatment was superior to ribavirin plus conventional treatment in terms of length of recovering time of overall clinical symptoms, antipyretic rash and oral herpes[64]. Another study of 8 RCTs enrolled 926 children with HFMD showed similar results[65].

Multiple clinical evidence showed that Xiyanping injection plus conventional treatment for patients at the stage of neurological involvement (severe cases) is significantly superior to conventional treatment in reducing incidence of severe complications, shortening the mean antipyretic clearance time, promoting recovery of skin and oral mucosa[66],[67]. The results of another two RCTs on the application of interferon and Xiyanping injection in the treatment of severe HFMD complicated by viral encephalitis demonstrated that compared with ribavirin plus Xiyanping injection, the combination of interferon and Xiyanping injection could shorten the time of fever and rash, relieving headache and vomiting, abating the mental symptoms and recovering consciousness[68].

Recommendation 1: For children with HFMD characterized by fever and rash (including herpes), it is recommended to use Xiyanping injection or its combination with other drugs at the early stage (Level A).

Recommendation 2: While receiving symptomatic supportive treatment, children with severe HFMD complicated by viral encephalitis can be treated with Xiyanping injection and interferon, which can coordinate to exert the anti-inflammatory and antiviral effects, thereby reducing the incidence of severe complications of HFMD, relieving headache, vomiting and mental symptoms, and recovering the consciousness more quickly (Level B).

3.7. Acute infectious diarrhea

Diarrhea is one of the five leading causes of children deaths in the world[69],[70],[71],[72]. Acute infectious diarrhea in children is often caused by virus infection, among which the most commonly detected ones are rotavirus and norovirus. Bacterial pathogens include Escherichia coli, Campylobacter, Salmonella and Shigella. A meta-analysis of 18 RCTs included 3 557 children with rotavirus enteritis showed that Xiyanping injection group showed a higher total effective rate, higher negative conversion rate of rotavirus, shorter antipyretic time and duration of diarrhea than the ribavirin group; 6 of 18 RCTs reported adverse events, and there were no significant difference in the incidence of adverse events between groups[73]. Another meta-analysis of 30 RCTs included 5 320 children with rotavirus enteritis showed that compared with ribavirin, Xiyanping injection could greatly shorten the time of diarrhea, fever and dehydration correction, and had a higher total effective rate for children with rotavirus enteritis, but the adverse events rates between Xiyanping injection and ribavirin were not significantly different[74]. To evaluate the efficacy and safety of Xiyanping injection combined with montmorillonite powder, a meta-analysis of 17 RCTs included 1 841 children with diarrhea, suggested that Xiyanping injection combined with montmorillonite powder had a higher total effective rate, and shorter time for diarrhea to relieve, body temperature to decrease, and stool property to return to normal[75].

Most cases of adult acute diarrhea are caused by viruses infection, which has a short disease duration and can be cured by symptomatic treatment, so many patients do not seek medical help. For adults with severe diarrhea, the majority of cases are caused by bacterial etiology, which requires antibiotic treatment. The results of 3 RCTs on the application of Xiyanping injection combined with levofloxacin in the treatment of adult acute bacillary dysentery showed that compared with using levofloxacin alone, the combined drugs could improve the total effective rate, and shorten the time for fever and diarrhea to relieve and the blood cell counts to restore normal levels[76],[77],[78]. Another control study on the treatment of adult bacillary dysentery by Xiyanping injection-combined lomefloxacin aspartate showed that he effective rate of combined drugs group is higher than that of Lomefloxacin aspartate alone group, and the antipyretic, antidiarrheal time were also faster than that of the control group[79].

Recommendation 1: As most cases of children with acute infectious diarrhea are caused by virus infection, it is recommended to use Xiyanping injection at the early stage to help relieve fever and shorten the duration of diarrhea (Level A).

Recommendation 2: For adults with severe acute infectious diarrhea, Xiyanping injection combined therapy is reccommended on the basis of empirical and specific antibiotic treatment to exert the synergistically anti-inflammatory and anti-pyretic effects (Level B).


  4. Rational Usage of Xiyanping Injection Top


4.1. Route and Dose of Administration

Xiyanping injection is commonly given by intravenous drip, or intramuscular injection.

For adult patients: intravenous drip, once a day, daily dose: 500 mg or less, dripping speed: 30-60 drops/min (recommended by the consensus); intramuscular injection, 2-3 times a day, 50-100 mg once.

For children patients: intravenous drip, once a day, daily dose calculated by body weight (5-10 mg/kg or 0.2-0.4 mL/kg), adjusted within that range according to the disease progressing and severity, 250 mg a day or less, dripping speed: 30-40 drops/min; intramuscular injection, twice a day, daily dose: 200 mg or less.

4.2. Administration method

Intravenous drip: Xiyanping injection is recommended to be diluted with 0.9% sodium chloride injection or 5% glucose injection before intravenous drip. The stability experiments with 0.9% sodium chloride injection and 5% glucose injection showed that when the dosage ratio of Xiyanping injection and 5% glucose injection exceeds 750 mg: 250 mL, the insoluble particles increased significantly, and 4 h after Xiyanping injection was mixed with 0.9% sodium chloride injection or 5% glucose injection, significant increase in the insoluble particles was observed. Therefore, the concentration of Xiyanping injection for intravenous drip is recommended to be 3 mg/mL, and Xiyanping injection in 0.9% sodium chloride injection or 5% glucose injection should be used up within 4 h[80].

Intramuscular injection: there is no need to dilute Xiyanping injection when injected by intramuscular; the injection is recommended to be given to children over 3 years old through gluteus maximus, gluteus medius, gluteus minimus, vastus lateralis or deltoid muscle; for 1-2years-old children, the medicine should not be injected through gluteus maximus, but gluteus medius or gluteus minimus.

4.3. Course of treatment

(1) For both children and adult patients, Xiyanping injection alone or Xiyanping injection-combined drugs should be used at the early stage of acute infection. The course of treatment, which is generally 3-7 days, depends on the disease severity and patients’ response to the treatment.

(2) Xiyanping injection is not recommended for the infection at chronic phase or use for a long-term (≥28 days).

4.4. Combined administration

(1) The active component of Xiyanping injection is andrographolide sulfonate, which has the efficacy of reducing heat and detoxifying. It is not recommended to be used in combination with other traditional Chinese medicine injections of similar efficacy.

(2) Previous studies on drug compatibility showed that when Xiyanping injection and drugs including vitamin C injection, cefazolin sodium pentahydrate for injection, ambroxol for injection and dexamethasone sodium phosphate injection were mixed at a high concentration, The mixture is turbid or particles appear. Therefore, the dosage and the above mentioned drugs should be carefully decided. If combination medication is needed, it is recommended to flush the infusion tube with 5% glucose injection or 0.9% sodium chloride injection; when a new drug is applied, use a new infusion ware to avoid the occurrence of adverse reactions caused by drug interactions.


  5. Safety of Xiyanping Injection Top


5.1. Adverse reaction (ADR)

Adverse reaction incidence: According to literature review, spontaneously reported data (SRS), and large-scale prospective active monitoring data, although the incidence of ADR varies in different data sources, the overall incidence of adverse reactions is between 0.075% and 2.110%[81]. According to the grading standard of ADR rate recommended by Council for International Organizations of Medical Sciences (CIOMS), Xiyanping injection seldom or rarely induce adverse reactions. However, a large-scale prospective active monitoring study showed that the ADR rate of children under 4 years old injected with Xiyanping injection was 0.073% (12/16 501). For children between 4 and 14 years old injected with Xiyanping injection the ADR rate was 0.079% (3/3 792). No significant differences in ADR rates were observed between these two age groups and that of the young and the middle- aged patients injected with Xiyanping injection, which was 0.066% (5/7 582)[82]. However, the ADR rate of the elderly and patients with hepatorenal insufficiency is not clear.

Adverse reactions of Xiyanping injection mainly occur on skin and its appendages (48.92%) or all over the body (17.97%)[83]. Symptoms such as skin rash, pruritus, shiver and antipyretic are common ADR and can be cured by drug withdrawal or symptomatic treatment. No significant differences in the type and severity of ADR were observed between children and adult patients.

5.2. Severe adverse reaction

Severe adverse reactions of Xiyanping injection account for about 3.72% of the total adverse reactions, and the main clinical manifestations are anaphylactic shock, shiver, expiratory dyspnea, etc[83]. Literature and research analysis showed that there was a higher risk for patients with a history of drug allergy to use Xiyanping injection. It is recommended to inquiry whether a patient had a history of drug allergy before using Xiyanping injection, close attention should be paid to observe and monitor the medication response in patients who are given the injection for the first time.

Severe anaphylactic reactions should be handled with reference to the Proposal of the Emergency Management Guideline (2014)[84] and Guideline for Emergency Management of Anaphylaxis[85] issued by European Academy of Allergy and Clinical Immunology (EAACI).

5.3. Precautions and contraindications

(1) If patients have allergic reactions or other serious adverse reactions after using Xiyanping injection, the treatment must be stopped immediately and proper therapy should be applied in time.

(2) Xiyanping injection and its mixture combined with other drugs should be checked carefully before use, after preparation and during the medication. If the drug solution changes such as turbidity, precipitation, discoloration, crystallization, etc., or there are air leakage and cracks on the bottle, the solution shall not be used. The diluted mixture should be used within 4 hours after its preparation.

(3) It is strictly prohibited to mix and match Xiyanping injection together with other drugs and use them with caution if combined medication is needed, flush the infusion tube with a 5% glucose injection or a 0.9% sodium chloride injection; please use a new infusion set when a new drug is applied to avoid adverse reactions caused by drug interactions.

(4) It is recommended to inquiry whether a patient had a history of being allergic to Xiyanping injection or other drugs, and whether they had allergic constitution or a family allergic history. If the answer is yes, Xiyanping injection mustnot be used. In addition, for patients with liver and kidney dysfunction, the elderly aged 75 or above, breastfeeding women and children (1-2 years old), the injection should be used cautiously, and surveillance should be strengthened when the injection was given to a patient for the first time.

5.4. Population under special conditions

Pregnant woman: Since there is no study conducted on the application of Xiyanping injection in pregnant women, effects and adverse reactions remain unknown and the injection is not recommended for pregnant women.

Children: It is not recommended to use Xiyanping injection in Children. Ssince the safety of Xiyanping injection for children under 12 months has not been proven, it must not be used in this age group of children;. Xiyanping injection used in children between 1-2 years old should be monitored with caution.

The elderly: The elderly patients over 75 years old are advised to use Xiyanping injection with caution because this treatment often impairs kidney function.

Appendix: List of consensus members

Fengbing Cai, Chenglou Cao, Desheng Cao, Yu Cao, Yanfen Chai, Bojun Chen, Fenqiao Chen, Haiming Chen, Xiaohui Chen, Yang Chen, Min Deng, Yangjia Deng, Zhe Deng, Banghan Ding, Bangjiang Fang, Xiaolei Fang, Li Fang, Wei Guo, Mingfeng He, Xiaojun He, Shaohong Hu, Shixiang Hu, Xiaomin Huang, Ruwen Jiang, Longyuan Jiang, Li Kong, Xiaoning Lei, Hongchun Leng, Dianhong Li, Fang Li, Guiwei Li, Hui Li, Jun Li, Xiaogang Li, Xu Li, Xucheng Li, Yupeng Li, Zhijun Li, Qun Liang, Zijing Liao, Weimin Liao, Yong Lin, Feng Ling, Bin Liu, Nan Liu, Qingquan Liu, Wanyan Liu, Xinqiao Liu, Yuntao Liu, Jianhua Lu, Jianqi Lu, Yun Lu, Zhenchun Luo, Chuanzhu Lv, Junqi Ma, Zhengrong Mao, Jianqiang Mei, Wensheng Qi, Zhilong Qiao, Xiaoyuan Qu, Qinglin Rui, Jun Shen, He Su, Xiaolan Tan, Guanghua Tang, Youqing Tang, Dawei Wang, Wei Wang, Aizhen Wen, Dan Wen, Caijun Wu, Fanwei Wu, Hui Wu, Xiaotu Xi, Yang Xie, Honghui Xu, Jun Xu, Guoliang Yan, Rongyuan Yang, Yandong Yan, Zhixu Yang, Weihai Yao, Wenping Ye, Yong Ye, Hongke Zeng, Zhongyi Zeng, Hong Zhan, Hanhong Zhang, Honglei Zhang, Jianping Zhang, Rongzhen Zhang, Wenwu Zhang, Xiaoyun Zhang, Xinchao Zhang, Yongbiao Zhang, Zhongde Zhang, Xiaodong Zhao, Rongbin Zhou, Xueliang Zhou.

Cordinator: Yuntao Liu.

Conflict of interest statement

We declare that we have no conflict of interest.

Authors’ contributions

The corresponding authors organized and drafted the consensus.

Other members made comments and suggestions on the final version of this consensus.



 
  References Top

1.
Wang SC, Chen ZG, Xu S. Guidelines for TCM diagnosis and treatment of children virus pneumonia. J Nanjing Univ Chin Med 2011; 27 (04): 304308.  Back to cited text no. 1
    
2.
Ma R, Wang XF, Yu JE, Huang JF, Wan CM, Cui ZZ, et al. Expert consensus on the application of integrated traditional Chinese and Western Medicine in the treatment of acute fever in children. Chin Pediatr Integr Tradit West Med 2012; 4 (01): 1-4.  Back to cited text no. 2
    
3.
Wang SC, Wang L, Shang LL. Clinical diagnosis and treatment guideline of Chinese pediatrics: Hand-foot-and-mouth Disease (revised). World Chin Med 2016; 11 (04): 734-740.  Back to cited text no. 3
    
4.
Wang SC, He LL, Sun LP. Guideline for clinical diagnosis and treatment of pediatrics of traditional Chinese medicine-varicella (Amendment). J Pediatr Tradit Chin Med 2016; 12 (1): 1-6.  Back to cited text no. 4
    
5.
Ding Y, Yan YB, Han SS, Zhen HT. Guideline for TCM pediatrics clinical diagnosis and treatment-bacillary dysentery in children (formulation). J Pediatr Tradit Chin Med 2017; 13 (4): 1-6.  Back to cited text no. 5
    
6.
Liu HM, Ma R. Expert consensus on the application of integrated traditional Chinese and Western Medicine in the treatment of Mycoplasma pneumonia in children (formulated in 2017). Chin J Pract Pediatr 2017; 32 (12): 881-885.  Back to cited text no. 6
    
7.
General Office of the Ministry of Health. Diagnosis and treatment program of H1N1 influenza (2010) [Online]. 2010. Available from: http://www.nhc.gov.cn/wjw/gkml/gkml. shtml,2010-04-30/2019-02-21. [Accessed on February 7 th 2020].  Back to cited text no. 7
    
8.
Ministry of Health of the People’s Republic of China. Guidelines for the diagnosis and treatment of hand-foot-and-mouth disease (2010) (continued). Zhejiang J Integr Tradit Chin West Med 2012; 22 (8): 654-669.  Back to cited text no. 8
    
9.
Ministry of Health of the People’s Republic of China. Guideline for the prevention and treatment of severe fever with thrombocytopenia syndrome (2010) issued by the Ministry of Health. China Pharm 2010; 21 (42): 3990.  Back to cited text no. 9
    
10.
General Office of the Ministry of Health. Guideline for diagnosis and treatment of Enterohemorrhagic E. O104:H4 infection (trial) [Online]. 2011. Available from: http://jkzx.lishui.gov.cn/jikzs/cdcrb/201106/t20110628_195836.htm [Accessed on Feb 7th 2020].  Back to cited text no. 10
    
11.
State Administration of Traditional Chinese Medicine. TCM prevention and treatment plan for common cold (influenza B) in 2012 (trial) [Online]. 2012. Available from: http://yzs.satcm.gov.cn/gongzuodongtai/2018-03-24/2906.html [Accessed on Feb 7th 2020].  Back to cited text no. 11
    
12.
Xiong XD, Qian YM, Lu YM, Wang Q, Li SF, Xie F, et al. Expert consensus on the application of integrated traditional Chinese and Western medicine in the treatment of community acquired pneumonia (2014). Chin J Integr Tradit West Med Intensive Crit Care 2015; 22 (1): 1-6.  Back to cited text no. 12
    
13.
Xiong XD, Xie F, He M, Shi R, Wang HH, Chen Q. Guidelines for integrated Traditional Chinese and Western medicine in the treatment of community-acquired pneumonia (basic edition of Shanghai 2015). Shanghai J tradit Chin Med 2016; 50 (7): 15-20.  Back to cited text no. 13
    
14.
General Office of National Health and Family Planning Commission. Diagnosis and treatment program for H7N9 avian influenza in human ( first edition, 2017). [Online]. Available from: https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2017&filename= CRBX201701003&v=MzIwNTQ5Rlo0UjhlWDFMdXhZUzdEaDFUM 3FUcldNMUZyQ1VSN3FmWmVab0Z5dm5XNzNBSmovSmRyRzRIO WJNcm8=[Accessed on Feb 7th 2020].  Back to cited text no. 14
    
15.
Wang ZF, Xie YM. Adverse event case reports for Xiyanping injection based on literature. China J Chin Mater Med 2012; 37 (18): 2792-2795.  Back to cited text no. 15
    
16.
Yang M. Analysis on the use of Xiyanping injection in outpatient and emergency department. Strait Pharm J 2012; 24 (10): 221-223.  Back to cited text no. 16
    
17.
Zhang L, Fang Y, Chen B, Su KJ, Lin YN, Chen GH. Analysis on the use of Xiyanping injection in Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine in 2014. Her Med 2016; 35 (suppl): 139141.  Back to cited text no. 17
    
18.
Liu WL, Zhang XW, Zhang B. Clinical analysis of 120 cases of incompatibility of xiyanping injection with different drug. China Pharm 2017; 26 (22): 84-85.  Back to cited text no. 18
    
19.
Xia Q, Huang FH, Lin Y, Liu M. Analysis of the use of traditional Chinese medicine injection in outpatient and emergency departments of pediatrics in a hospital. Chin J Clin Ration Drug Use 2016; 9 (2): 71-72.  Back to cited text no. 19
    
20.
Chong L, Luo YH, Yang XL, Cheng F, Chen WK. Tissue distribution of sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate in rats in vivo. Chin Tradit Patent Med 2013; 35 (11): 2378-2384.  Back to cited text no. 20
    
21.
Chong L. Pharmacokinetics and tissue distribution of active components of Xiyanping injection in rats. Ph.D dissertation. Submitted to Nanchang University, 2013. DOI: 10.7666/d.Y2427650.  Back to cited text no. 21
    
22.
Wang SY, Ping J, Xie N, Chen X, Wang XF. Evaluation of in vitro antiinfluenza virus efficacy of andrographolide sulfonate. Cent South Pharm 2013; 11 (5): 331-334.  Back to cited text no. 22
    
23.
Ping J, Wang SY, Xie N, Chen X, Wang XF. A study of anti-adenovirus effect of andrographolide sulfonated in vitro. Chin J ETMF 2012; 18 (21): 175-179.  Back to cited text no. 23
    
24.
Guan C, Li M, Ren QJ, Zhang W, Shang MM, Wang RB, et al. Andrographolide protects mice against severe enterovirus 71 infection by its anti-inflammation and immunomodulation effect. Immunol J 2013; 29 (9): 737-744.  Back to cited text no. 24
    
25.
Li L, Wang YP, Zhao J, Jiang M, Lv C, Lv AP. Bioinformatics analysis on molecular mechanism of Xiyanping injection for H1N1 influenza A. J Tradit Chin Med 2014; 55 (4): 337-341.  Back to cited text no. 25
    
26.
Lu C, Liu XR, Ding XR, Chen X, Fan HW, Liu YQ, et al. A metabolomics profiling study in hand-foot-and-mouth disease and modulated pathways of clinical intervention using liquid chromatography/ quadrupole time-of-flight mass spectrometry. Evid Based Complement Altern Med 2013; 2013: 647452.  Back to cited text no. 26
    
27.
Wen T, Xu WJ, Liang LC, Li JH, Ding XR, Chen X, et al. Clinical efficacy of andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease (HFMD) is dependent upon inhibition of neutrophil activation. Phytother Res 2015; 29 (8): 1161-1167.  Back to cited text no. 27
    
28.
Chen T, Mao YD, Ma N, Shen MX, Zeng JN, Jiang CH, et al. Evaluation of anti-enterovirus efficacy of andrographolide and its derivatives. China Pharm 2019; 22 (4): 635-639.  Back to cited text no. 28
    
29.
Yu Y, Cong Y, Quan XD, Wei J. Pharmacodynamics of Xiyanping injection. J Liaoning Univ Tradit Chin Med 2009; 11 (7): 198-200.  Back to cited text no. 29
    
30.
Ma CS, Duan CJ, Ma JJ. Research progress of the pharmacological activity of andrographolide and its derivatives. Jilin J Tradit Chin Med 2014; 34 (1): 77-81.  Back to cited text no. 30
    
31.
Li SG, Ye ZY. Pharmacological activity of andrographolide. Chinese Arch Tradit Chin Med 2008; 5: 984-986.  Back to cited text no. 31
    
32.
Li QR, Zhang P, Wu YY, Ma J, Wang XX, He M. Antibacterial activity in vitro of Xiyanping injection combined with 7 kinds of antibiotics. China Pharm 2017; 20 (6): 1136-1138.  Back to cited text no. 32
    
33.
Wu ZQ, Ma R, Ping J, Wang SY, Yue ZJ. Effect of Xiyanping on the secretion of inflammatory factors by A549 cells infected with Mycoplasma pneumonia. Chin Tradit Patent Med 2016; 38 (11): 24842487.  Back to cited text no. 33
    
34.
Peng S, Huang N, Liu W, Guo WJ, Jiang CH, Yang XL, et al. Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-kB pathways. Acta Pharm Sin B 2016; 6 (3): 205-211.  Back to cited text no. 34
    
35.
Gao J, Peng S, Liu W, Jiang CH, Yang XL, Sun Y, et al. Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROSmediated NF-kB signaling and NLRP3 inflammasome activation. Oncotarget 2016; 7 (49): 80262.  Back to cited text no. 35
    
36.
Nie YL, Yang XL, Li ZY, Yu YH, Fan B, Yan H, et al. Effects of cytokine content of Xiyanping injection on acute lung injury induced by LPS in rat bronchoalveolar lavage. Chin J Basic Med Tradit Chin Med 2012; 18 (9): 976-978.  Back to cited text no. 36
    
37.
Wang MY, Li YH, Jin R, Guo S, Wu LX, Fan XY, et al. Effect of andrographolide on expressions of inflammatory cells, interleukin-12 and interleukin-13 in bronchoalveolar larage fluid of asthmatic mice model. J Appl Clin Pediatr 2012; 27 (21): 1644-1646.  Back to cited text no. 37
    
38.
Guo WJ, Liu W, Chen G, Hong SC, Qiao C, Xie N, et al. Water- soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-kB pathways. Int Immunopharmcol 2012; 14 (4): 613-619.  Back to cited text no. 38
    
39.
Liu W, Guo WJ, Guo LL, Gu YH, Cai PF, Xie N, et al. Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/ Th17 response. Int Immunopharmacol 2014; 20 (2): 337-345.  Back to cited text no. 39
    
40.
Ren XL, Li AP, Li XH, Wang YP, Wang Q, Zhong ML, et al. Curative effects on Xiyanping injection versus Ribavirin for acute upper respiratory infection in children: A Meta-analysis. Chin Tradit Patent Med 2017; 39 (3): 480-485.  Back to cited text no. 40
    
41.
Xu JL, Liang ZR, Guo ZL, Li ZC, Deng LM. Xiyanping combined with ribavirin in treatment of children with pediatric herpangina. Chin J Exp Tradit Med Form 2016; 22 (4): 195-200.  Back to cited text no. 41
    
42.
Chen XF. Observation of the effect of Xiyanping in the treatment of acute suppurative tonsillitis. Contemp Med Forum 2014; 12 (10): 123.  Back to cited text no. 42
    
43.
Jiang J, Yang T. Clinical observation of Xiyanping injection and antibiotic treatment of acute suppurative tonsillitis. Chin J Clin Ration Drug Use 2012; 5 (3B): 38-39.  Back to cited text no. 43
    
44.
Wang W. Observation of efficacy of Xiyanping injection in treating acute tonsillitis. Modern Med & Health Res 2018; 2 (13): 130.  Back to cited text no. 44
    
45.
Song P, Xu J, Qiu JL, Luo ZH, Wang DW, Liu YT, et al. A meta analysis of Xiyanping injection combined with oseltamivir in the treatment of influenza. J Emerg Tradit Chin Med 2019; 51 (8): 28-32.  Back to cited text no. 45
    
46.
Xu J, Luo ZH, Qiu JL, Wang DW, Liu YT, Zhang ZD. Meta-analysis of Xiyanping injection on influenza. J Emerg Tradit Chin Med 2019; 2019 (8). DOI: 10.3969/j.issn.1004-745X.2019.08.007.  Back to cited text no. 46
    
47.
Creer DD, Dilworth JP, Gillespie SH, Johnston AR, Johnston SL, Ling C, et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006; 61: 75.  Back to cited text no. 47
    
48.
MacKay DN. Treatment of acute bronchitis in adults without underlying lung disease. Gen Intern Med 1996; 11: 557.  Back to cited text no. 48
    
49.
Harris AM, Hicks LA, Qaseem A. High value care task force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: Advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016; 164: 425.  Back to cited text no. 49
    
50.
National Quality Forum (NQF). Avoidance of antibiotic treatment in adults with acute bronchitis. [Online]. Available from: http://www. quality orum. org/Measure Details. aspxactid=0&SubmissionId=1216#p=5&s=n&so=a [Accessed on 4th October 2017].  Back to cited text no. 50
    
51.
Choosing Wisely Canada. American College of Emergency Physicians. Avoid wound cultures in emergency department patients with uncomplicated skin and soft tissue abscesses after successful incision and drainage and with adequate medical follow-up. [Online]. 2013. Available from: http://www.Choosing wisely canada. org/recommendations/emergency-medicine/ [Accessed on 16th March 2017].  Back to cited text no. 51
    
52.
Pulmonary Diseases Branch of China Association of Chinese Medicine, Pulmonary Diseases Branch of China Medical Association of Minorities. Guideline for TCM diagnosis and treatment of acute tracheobronchial inflammation (2015). J Tradit Chin Med 2016; 57 (9): 806-810.  Back to cited text no. 52
    
53.
Zhang CH. Comparison of clinical efficacy of Xiyanping injection and Tanreqing Injection in the treatment of elderly patients with acute bronchitis. Clin Med 2018; 2018 (12): 61-63.  Back to cited text no. 53
    
54.
Wang YM, Lu L, Fan HW, Xu HF. Meta-analysis on effectiveness and safety of Xiyanping injection combined with antibiotics in treatment of CAP in adults. Chin Tradit and Herb Drugs 2018; 49 (2): 468-476.  Back to cited text no. 54
    
55.
Li XL, Fang SN, Wang LY, Li DM, Yu XQ. Meta-analysis of the efficacy of Xiyanping injection-combined azithromycin in the treatment of community acquired pneumonia in the elderly. Tradit Chin Med Res 2017; 30 (12): 69-72.  Back to cited text no. 55
    
56.
Xiong XD, Xie F, He M, Shi R, Wang HH, Chen Q. Guideline for treatment of community acquired pneumonia by integrated traditional Chinese and Western Medicine (Edition for Shanghai grassroots community, 2015). Shanghai J Tradit Chin Med 2016; 50 (7): 15-20.  Back to cited text no. 56
    
57.
Xie HH, Qi B, Du LN, Wang SC. Efficacy and safety of Xiyanping injection in treatment of children viral pneumonia: A meta-analysis. Lishizhen Med Mater Med Res 2014; 25 (10): 2546-2549.  Back to cited text no. 57
    
58.
Qi RH, Fang SN, Li DM, Zhang HC. System evaluation and meta analysis of Xiyanping injection in the treatment of adult viral pneumonia. Mod Chin Clin Med 2018; 25 (3): 29-33..  Back to cited text no. 58
    
59.
Liu J, Huang H. Summary of the pharmacological characteristics of Xiyanping injection and clinical studies on respiratory diseases. Health World 2014; 2014 (8): 48-51.  Back to cited text no. 59
    
60.
Wang Y. The clinical observation of Xiyanping injection even treatment coughs of 132 examples. China Mod Med 2009; 16 (23) :56-57.  Back to cited text no. 60
    
61.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2017 Report). 2017. [Online]. Available from: http:// www. goldcopd. Org. [Accessed on 7 th Feb 2020].  Back to cited text no. 61
    
62.
Expert Group for AECOPD Diagnosis and Treatment. Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (updated in 2017). Int J Respir 2017; 37 (14): 1041-1057.  Back to cited text no. 62
    
63.
Special Committee of Pulmonary Diseases, Internal Medicine Branch of China Association of Chinese Medicine. Guideline for TCM diagnosis and treatment of chronic obstructive pulmonary disease (2011). J Tradit Chin Med 2012; 53 (1): 80-84.  Back to cited text no. 63
    
64.
Liu BB, Hua LX, Dong Y, Yao C. Evaluation and meta analysis of Xiyanping and Ribavirin treatment of hand-foot-and-mouth disease. Chin J ETMF 2014; 20 (9): 231-236.  Back to cited text no. 64
    
65.
Xu C, Wu TC, Liao Y, Song J, Huang F, Zhao KJ. Meta-analysis of the therapeutic effect of Xiyanping injection combined with interferon in the treatment of pediatric hand-foot-mouth disease. Mod Chin Doct 2017; 55 (2): 45-49.  Back to cited text no. 65
    
66.
Li XH, Zhang C, Shi QS, Yang T, Zhu QX, Tian YM, et al. Improving the efficacy of conventional therapy by adding andrographolide sulfonate in treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid Based Complement Altern Med 2013; 2013 (4): 316250.  Back to cited text no. 66
    
67.
Zhao L, Zhang LX, Liang XJ. Efficacy of Xiyanping combined with gamma globulin in the treatment of severe hand-foot-and-mouth disease and effect on PCT, CRP and myocardial enzyme in children. Chin J Ration Drug Use 2018; 15 (9): 32-34.  Back to cited text no. 67
    
68.
Zhu Y, Ye HZ. Efficacy of recombinant human interferon-combined Xiyanping in the treatment of severe hand-foot-and-mouth disease complicated by viral encephalitis. Zhejiang J Integr Tradit Chin West Med 2011; 21 (4): 260-262.  Back to cited text no. 68
    
69.
Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, et al. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010, a data synthesis. PLoS Med 2015; 12: e1001921.  Back to cited text no. 69
    
70.
World Health Organization. Top 10 causes of death, global health observatory data, 2017. [Online]. Available from: http://www.who.int/gho/mortality burden disease/causes death/top_10/en/ [Accessed on 20 th June 2017].  Back to cited text no. 70
    
71.
Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013; 381: 1405.  Back to cited text no. 71
    
72.
Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn E, et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151.  Back to cited text no. 72
    
73.
Jia X, Wang JC, Liu HG, Song DM, Duo HY, He BP. Comparative effectiveness and safety of xiyanping with ribavirin for rotavirus enteritis therapy in childhood: A systematic review and meta-analysis. Trop J Pharm Res 2018; 17 (1): 169-177.  Back to cited text no. 73
    
74.
Xu Y, Ge YC, Xie JD, Zhong M, Xu C. The meta-analysis and treatment strategies of the clinical efficacy for Xiyanping injection in the treatment of children rotavirus enteritis. Mod Chin Doct 2017; 55 (9): 14-19.  Back to cited text no. 74
    
75.
Xu JL, Li ZC, Liang ZR, Guo ZL, Deng LM. Meta-analysis on clinical efficacy and safety of Xiyanping combined with montmorillonite power in treatment of infantile diarrhea. Chin J ETMF 2016; 22 (3): 211-216.  Back to cited text no. 75
    
76.
Chen X. Efficacy of levofloxacin hydrochloride-combined Xiyanping in the treatment of adult acute bacillary dysentery. China Prescript Drug 2017; 15 (7): 87-88.  Back to cited text no. 76
    
77.
Zhang WD. Efficacy of levofloxacin hydrochloride-combined Xiyanping in the treatment of adult acute bacillary dysentery. Cap Med 2019; 9: 6162.  Back to cited text no. 77
    
78.
Wang W, Ma CL. Observation on the efficacy of levofloxacin hydrochloride-combined Xiyanping in the treatment of 40 cases of adult acute bacillary dysentery. Chin Community Doct, Med Spec 2011; 13 (5): 39-40.  Back to cited text no. 78
    
79.
Feng X. Efficacy of Xiyanping-combined lomefloxacin aspartate in the treatment of adult bacillary dysentery. Chin J Misdiagn 2008; 8 (7): 15621563.  Back to cited text no. 79
    
80.
Yu Y, Cong Y, Quan XD, Wei J. Pharmacodynamics studies of Xiyanping for injection. J Liaoning Univ of Tradit Chin Med 2009; 11 (7): 198-200.  Back to cited text no. 80
    
81.
Chen R, Zhuo L, Pan YT, Cai T, Cao Y, Wang SF. Features of adverse drug reaction in post-marketing study about Xiyanping injection based on literature. Chin J Pharmacoepidemiol 2018; 27 (5): 317-323.  Back to cited text no. 81
    
82.
Deng JX, Wang ZF, Xie YM, Li B, Ma L, Wang JC, et al. Post-marketing safety reevaluation of Xiyanping injection. Adverse Drug React J 2018; 20 (1): 15-22.  Back to cited text no. 82
    
83.
Wang ZF, Xiang YY, Xie YM. Research on early warning signals of adverse drug reactions to parenterally administered Xiyanping based on spontaneous reporting system (SRS) data. China J Chin Mater Med 2013; 38 (18): 3008-3012.  Back to cited text no. 83
    
84.
Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, et al. The management of anaphylaxis in childhood: Position paper of the European academy of allergology and clinical immunology. Chin J Allergy Clin Immunol 2009; 3 (1): 68-77.  Back to cited text no. 84
    
85.
Li XT, Zhai SD, Wang Q, Wang YQ, Yin J, Chen YG, et al. Recommendations in guideline for emergency management of anaphylaxis. Adverse Drug React J 2019; 21 (21): 85-91.  Back to cited text no. 85
    



 
 
    Tables

  [Table 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  2. Basic Informa...3. Suggestions o...4. Rational Usag...5. Safety of Xiy...
  In this article
Abstract
1. Introduction
References
Article Tables

 Article Access Statistics
    Viewed1409    
    Printed44    
    Emailed0    
    PDF Downloaded165    
    Comments [Add]    

Recommend this journal